-
Posted by
Two Blokes Jun 13 -
Filed in
Stock
-
4 views
Corcept Therapeutics remains a strong buy, with recent stock weakness attributed to put options trading rather than fundamental issues. Management maintains aggressive 2025 and long-term revenue guidance, supported by increased testing, salesforce expansion, and a backlog of prescriptions. The company is submitting a New Drug Application for Relacorilant in ovarian cancer, opening a new oncology revenue stream beyond endocrinology.
